Double-blind study of tolerability and antibody production of unmodified and chemically modified allergen vaccines of Phleum pratense

被引:19
作者
Casanovas, M [1 ]
Sastre, J
Fernández-Nieto, M
Lluch, M
Carnés, J
Fernández-Caldas, E
机构
[1] Lab LETI SL, Madrid, Spain
[2] Fdn Jimenez Diaz, Allergy Unit, E-28040 Madrid, Spain
关键词
allergens; asthma rhinitis; depigmented-polymerized allergen extracts; immunotherapy; Phleum pratense; tolerability;
D O I
10.1111/j.1365-2222.2005.02343.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 [免疫学];
摘要
Background The physicochemical modification of allergen extracts provides a chance for administering higher doses of allergen vaccines. Objective To evaluate the safety of a chemically modified (depigmented-glutaraldehyde polymerized) therapeutic vaccine of Phleum pratense administered at doses that are 10 times higher than those used in clinical practice, in comparison with conventional doses of the corresponding non-modified alum-adsorbed vaccine. Material and methods The design of the study was randomized, double-blind, parallel and included two groups of patients. Twenty-three patients were treated weekly during nine visits for the build-up phase, followed by two weekly maintenance doses (a total of 11 injections per patient). Twelve patients received a vaccine containing the standardized unmodified extract, at a maximum concentration of 308.5 mcg of freeze dried material/mL (Group A). Eleven patients received a standardized modified allergen extract (Group B). The maximum dose used was 2400 mcg/mL. Safety was evaluated recording all adverse events. Skin test results and specific antibody levels were evaluated at the beginning and at the end of the study. Results Group A patients experienced three local immediate (two clinically irrelevant and one with a diameter > 5 cm) and 18 delayed reactions (15 irrelevant and three with a diameter > 10 cm), while Group B experienced six local immediate and 12 delayed reactions (all clinically irrelevant). Nine Group A patients experienced 12 systemic reactions (one immediate of grade 1, one of grade 2; and one delayed of grade 1; four of grade 2 and three of grade 3), while Group B patients experienced one immediate systemic reaction of grades 1, and 1 delayed reaction of grade 1. Conclusions The modified extract of P. pratense is safe to treat sensitive patients, even at concentrations that are 10 times higher than those regularly administered in clinical practice. The majority of the local reactions were clinically irrelevant. No systemic reactions of grade 2, 3 or 4 were reported using the modified extract.
引用
收藏
页码:1377 / 1383
页数:7
相关论文
共 42 条
[1]
Immunotherapy with depigmented glutaraldehyde-polymerized extracts:: changes in quality of life [J].
Alvarez-Cuesta, E ;
Aragoneses-Gilsanz, E ;
Martín-Garcia, C ;
Berges-Gimeno, P ;
Gonzalez-Mancebo, E ;
Cuesta-Herranz, J .
CLINICAL AND EXPERIMENTAL ALLERGY, 2005, 35 (05) :572-578
[2]
Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma [J].
Ameal, A ;
Vega-Chicote, JM ;
Fernández, S ;
Miranda, A ;
Carmona, MJ ;
Rondón, MC ;
Reina, E ;
García-González, JJ .
ALLERGY, 2005, 60 (09) :1178-1183
[3]
ANDRE FE, 1998, PRECLINICAL CLIN DEV
[4]
Berrens L., 1998, Allergy (Copenhagen), V53, P56
[5]
BERRENS L, 1994, Patent No. 9406821
[6]
Determination of Ole e 1 by enzyme immunoassay and scanning densitometry.: Validation by skin-prick testing [J].
Boluda, L ;
Sastre, J ;
Casanovas, M ;
Fernández-Caldas, E .
JOURNAL OF IMMUNOLOGICAL METHODS, 1999, 223 (01) :17-26
[7]
Boluda L, 1996, ALLERGY, V51, P706
[8]
EVALUATION OF THE POTENCY OF ALLERGENIC EXTRACTS BY INHIBITION OF IGG-ANTIBODY BINDING [J].
BOLUDA, L ;
GALLEGO, MT ;
ROMANO, MLG ;
CAMBRA, O ;
BERRENS, L .
BIOLOGICALS, 1994, 22 (02) :171-177
[9]
IMMUNOTHERAPY WITH A STANDARDIZED DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT .1. INVIVO AND INVITRO PARAMETERS AFTER A SHORT COURSE OF TREATMENT [J].
BOUSQUET, J ;
CALVAYRAC, P ;
GUERIN, B ;
HEJJAOUI, A ;
DHIVERT, H ;
HEWITT, B ;
MICHEL, FB .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1985, 76 (05) :734-744
[10]
SAFETY CONSIDERATIONS IN ASSESSING THE ROLE OF IMMUNOTHERAPY IN ALLERGIC DISORDERS [J].
BOUSQUET, J ;
MICHEL, FB .
DRUG SAFETY, 1994, 10 (01) :5-17